Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

Congress is leaving town for the holidays — and another year has gone by, with bipartisan pharmacy benefit manager legislation still on the flight deck.

The pharmaceutical sector's most intense rivalry is escalating. Eli Lilly has unveiled pivotal Phase 3 trial results for its ...

In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Distilling that complexity into a handful of trends has been no small task. What follows is not a definitive forecast, but ...

Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.

Danish pharma major Novo Nordisk has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for once-weekly CagriSema (cagrilintide and semaglutide) injection, to be used ...

The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...

The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

UnitedHealth Group has had a tumultuous year, marred by poor performance and controversy. Eli Lilly has thrived as it's taken ...

Health-care companies ticked up as traders rotated back into higher risk sectors. Eli Lilly shares rose after the maker of weight-loss drugs filed for U.S. Food and Drug Administration approval of a ...